China SXT Pharmaceuticals Inc (SXTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has a cash flow conversion efficiency ratio of -0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.26 Million) by net assets ($29.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SXTC equity to assets ratio to measure how much of total assets are equity-financed.
China SXT Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2026)
This chart illustrates how China SXT Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is China SXT Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
China SXT Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kudelski
SW:KUD
|
-0.143x |
|
Xchanging Solutions Limited
NSE:XCHANGING
|
0.045x |
|
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
|
-0.019x |
|
DOMESCO Medical Import Export JSC
VN:DMC
|
0.001x |
|
Starry Sea Acquisition Corp Ordinary Shares
NASDAQ:SSEA
|
-0.010x |
|
Sungdo Engineering & Construction Co. Ltd
KQ:037350
|
0.059x |
|
Aker Technology Co Ltd
TWO:6174
|
0.024x |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
0.032x |
Annual Cash Flow Conversion Efficiency for China SXT Pharmaceuticals Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of China SXT Pharmaceuticals Inc from 2016 to 2026. For the full company profile with market capitalisation and key ratios, see China SXT Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $29.71 Million | $-4.02 Million | -0.135x | +10.97% |
| 2025-03-31 | $15.44 Million | $-2.35 Million | -0.152x | -9.75% |
| 2024-03-31 | $13.93 Million | $-1.93 Million | -0.138x | -2417.87% |
| 2023-03-31 | $14.69 Million | $-80.76K | -0.005x | -133.65% |
| 2022-03-31 | $16.42 Million | $268.29K | 0.016x | +119.80% |
| 2021-03-31 | $15.96 Million | $-1.32 Million | -0.082x | -183.00% |
| 2020-03-31 | $9.40 Million | $934.25K | 0.099x | +361.48% |
| 2019-03-31 | $11.11 Million | $239.19K | 0.022x | -96.32% |
| 2018-03-31 | $3.29 Million | $1.92 Million | 0.584x | +269.46% |
| 2017-03-31 | $1.85 Million | $293.04K | 0.158x | -35.61% |
| 2016-03-31 | $742.77K | $182.47K | 0.246x | -- |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu,… Read more